SPARC in cancer biology: Its role in cancer progression and potential for therapy

被引:192
|
作者
Tai, Isabella T. [1 ,2 ]
Tang, Michelle J. [1 ,2 ]
机构
[1] Univ British Columbia, Div Gastroenterol, Vancouver, BC V5Z 1M9, Canada
[2] British Columbia Canc Agcy, Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada
关键词
Chemosensitization; 5-Aza-2 '-deoxycytidine; Albumin-binding protein; Promoter hypermethylation; SPARC;
D O I
10.1016/j.drup.2008.08.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The ability to effectively target a tumor to achieve complete regression and cure is the ultimate goal that drives our need to better understand tumor biology. Recently, SPARC has generated considerable interest as a multi-faceted protein that belongs to a family of matricellular proteins. It functions not only to modulate cell-cell and cell-matrix interactions, but its de-adhesive and growth inhibitory properties in non-transformed cells have led to studies to assess its role in cancer. Its divergent actions reflect the complexity of this protein, because in certain types of cancers, such as melanomas and gliomas, SPARC is associated with a highly aggressive tumor phenotype, while in others, mainly ovarian, neuroblastomas and colorectal cancers, SPARC may function as a tumor suppressor. Recent studies have also demonstrated a role for SPARC in sensitizing therapy-resistant cancers. Here, the role of SPARC in cancer progression and its potential application in cancer therapy is discussed. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:231 / 246
页数:16
相关论文
共 50 条
  • [31] Lgr5 in cancer biology: functional identification of Lgr5 in cancer progression and potential opportunities for novel therapy
    Xu, Liangliang
    Lin, Weiping
    Wen, Longping
    Li, Gang
    STEM CELL RESEARCH & THERAPY, 2019, 10 (1)
  • [32] THE DEVELOPMENT OF REGORAFENIB AND ITS CURRENT AND POTENTIAL FUTURE ROLE IN CANCER THERAPY
    Davis, S. L.
    Eckhardt, S. G.
    Messersmith, W. A.
    Jimeno, A.
    DRUGS OF TODAY, 2013, 49 (02) : 105 - 115
  • [33] The role of molecular biology in understanding ovarian cancer initiation and progression
    Bingham, C
    Roberts, D
    Hamilton, TC
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2001, 11 : 7 - 11
  • [34] Loss of SPARC in bladder cancer enhances carcinogenesis and progression
    Said, Neveen
    Frierson, Henry F.
    Sanchez-Carbayo, Marta
    Brekken, Rolf A.
    Theodorescu, Dan
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (02): : 751 - 766
  • [35] Tissue necrosis and its role in cancer progression
    Adi Karsch-Bluman
    Ariel Feiglin
    Eliran Arbib
    Tal Stern
    Hila Shoval
    Ouri Schwob
    Michael Berger
    Ofra Benny
    Oncogene, 2019, 38 : 1920 - 1935
  • [36] Tissue necrosis and its role in cancer progression
    Karsch-Bluman, Adi
    Feiglin, Ariel
    Arbib, Eliran
    Stern, Tal
    Shoval, Hila
    Schwob, Ouri
    Berger, Michael
    Benny, Ofra
    ONCOGENE, 2019, 38 (11) : 1920 - 1935
  • [37] Molecular Biology of Bladder Cancer Potential Implications for Therapy
    McConkey, David J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (03) : 457 - 468
  • [38] Dendritic cell biology and potential applications in cancer therapy
    Schmidt-Wolf, I
    BRITISH JOURNAL OF CANCER, 2003, 88 : S3 - S3
  • [39] Potential role of tetrandrine in cancer therapy
    Chen, YJ
    ACTA PHARMACOLOGICA SINICA, 2002, 23 (12) : 1102 - 1106
  • [40] Potential role of tetrandrine in cancer therapy
    CHEN Yu-JenDepartment of Radiation Oncology
    Acta Pharmacologica Sinica, 2002, (12) : 49 - 53